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ABSTRACT
The performance of the VITEK2 system was evaluated against the agar dilution reference procedure for
testing susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to macrolides, lincosamides
and streptogramins (MLS). Eighty clinical isolates were selected according to their resistance phenotype
and genotype. Results for erythromycin and clindamycin showed 100% agreement; results for
lincomycin showed agreement of 78%, with one very major error and 17 minor errors; and results for
pristinamycin showed agreement of 46%, with one major error and 43 minor errors. Most isolates
resistant to lincomycin and streptogramin A (L SgAr phenotype) were falsely susceptible to lincomycin,
and intermediately-resistant or resistant to pristinamycin, with the VITEK2 system. No resistance gene
was detected. Most (80%) isolates resistant constitutively to MLS (MLSrBC phenotype) were falsely
intermediately-resistant to pristinamycin with the VITEK2 system. The erm(A) gene was more common
than erm(C) in MLSrBC strains. Resistance to pristinamycin alone (SgA SgB PT
r phenotype), or associated
with either lincomycin resistance (L SgA SgB PTr phenotype) or constitutive MLSB resistance
(MLSBC SgA PT
r phenotype), was well-characterised without discordant results. Resistance to pristi-
namycin was always associated with resistance to streptogramin A, encoded by the vga(A), vga(B),
vgb(A) and vat(A) genes in association with the erm(A) or erm(C) genes.
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INTRODUCTION
Macrolides (e.g., erythromycin), lincosamides
(e.g., lincomycin and clindamycin) and streptog-
ramins (streptogramin A (SgA) and its related
compound pristinamycin (PT) IIA, and streptogr-
amin B (SgB) and its related compound pristina-
mycin IB) are members of the MLS family. These
antibiotics bind different targets in the peptidyl-
transferase domain of the 50S ribosomal subunit,
which leads to the inhibition of protein elongation
at different steps. A and B compounds act
synergically and become bactericidal when they
are used in association, mainly against Gram-
positive bacteria.
Pristinamycins are used for the treatment of
staphylococcal infections. Resistance to this group
of antibiotics is associated with numerous genes;
thus, modification of the target 23S rRNA by
methylases is encoded by the erm(A)–erm(B)–
erm(C) determinants. This resistance is either
inducible (resistance to 14- and 15-membered
ring agents; MLSrBi phenotype) or constitutive
(resistance including 16-membered ring agents;
MLSrBC phenotype). Staphylococcal resistance to
pristinamycin is associated with resistance to A
compounds, but not necessarily with resistance to
B compounds [1]. Seven genes and a variant that
inactivate type A streptogramin have been isola-
ted from staphylococcal plasmids. Among them,
five genes encode related acetyltransferases: vat
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(now named vat(A) [2,3]), vat(B) [4] and vat(C) [5],
and two other genes and a variant, which encode
related ATP-binding proteins involved in active
efflux, i.e., vga (renamed vga(A) [3,6]), vga(B) [7]
and the variant vga(Av) carried by a transposon,
Tn5406, found in staphylococci [8]. Rare staphylo-
coccal isolates, although susceptible to erythro-
mycin and clindamycin, are resistant specifically
to lincosamide and streptogramin A (L SgAr
phenotype); some of these isolates carry vga(Av)
alone [9]. The L SgA strains are rare, as they
represent < 1% of Staphylococcus aureus isolates
resistant to methicillin. Resistance to type B
streptogramin is mediated by two genes encoding
lactonases that inactivate the type B compound,
namely vgb (renamed vgb(A) [3,10]) and vgb(B) [5].
Different automated or semi-automated com-
mercial systems are used commonly for rapid
susceptibility testing of bacteria. Turn-around
and hands-on times are decreased compared
with conventional methods. The automated
VITEK2 system (bioMe´rieux, Marcy l’Etoile,
France) provides susceptibility testing categori-
sation within a few hours. This is achieved by
continuous monitoring of growth kinetics and
an algorithm to calculate the MIC [11]. In
addition, VITEK2 provides an expert system
(Advanced Expert System; AES) for biological
validation of susceptibility results and therapeu-
tic interpretation [12].
In this study, the performance of the VITEK2
system was evaluated against results obtained by
the agar dilution procedure for susceptibility
testing of MLS antibiotics against clinical isolates
of S. aureus and Staphylococcus epidermidis. The
isolates were selected according to their resistance
genotype for the MLS group of agents, as deter-
mined by PCR.
MATERIALS AND METHODS
Bacterial isolates
These comprised 62 clinical isolates of S. aureus and 18 of
S. epidermidis. All S. epidermidis and 46 S. aureus isolates were
collected from Hoˆtel-Dieu Hospital, Nantes, while the remain-
ing 16 isolates were collected from North Hospital, Saint-
Etienne, in 1999 and 2000. The isolates were selected according
to their resistance phenotype, and were screened for MLS
resistance genes by PCR. Two quality control strains were also
included, namely S. aureus ATCC 25923 and S. epidermidis
ATCC 12228, both of which were fully susceptible. Initial iden-
tification was based on colony and microscopic morphology,
and catalase and Staphyslide agglutination tests (bioMe´rieux).
S. epidermidis isolates were identified to the species level using
the identification card for Gram-positive cocci (ID-GPC card;
bioMe´rieux) on the VITEK2 system.
Detection of MLS resistance genes
Staphylococcal DNA was extracted by a cell lysis method
using lysozyme and lysostaphin [13]. DNA was dissolved in
TE buffer (10 mM Tris-HCl, 1 mM EDTA), and 5 lL of the
solution was used as a template in PCRs. The erm(A) and
erm(C) genes were detected by PCR using the oligonucleotide
primer pairs described by Sutcliffe et al. [14], yielding PCR
products of 654 bp and 642 bp, respectively. Primers specific
for vga(A), vgb(A), vat(A) and vat(B) [15] were also used,
yielding PCR products of 470 bp, 734 bp, 619 bp and 602 bp,
respectively. Additional primers were designed from pub-
lished GenBank sequences for: vga(B) (5¢-GAATAAGGCG-
CAAGGAATGA-3¢ and 5¢-TAGCTTGGCAAAAGCAACCT-3¢;
641-bp amplification product; GenBank accession number
U82085); vgb(B) (5¢-TGGTCCTTACGGAATAACGG-3¢ and
5¢-ATTTTTCCCCGCGGTTATAG-3¢; 432-bp amplification
product; GenBank accession number AF015628); and vat(C)
(5¢-GCCCCAATCCAGAAGAAATA-3¢ and 5¢-ACCGGGCA-
TAATTGTCACAT-3¢; 410-bp amplification product; GenBank
accession number AF015628). All oligonucleotides were syn-
thesised by Sigma Genosys (Cambridge, UK).
The 80 staphylococcal isolates displaying resistance to at
least one of the MLS antibiotics were analysed by PCR on a
GeneAmp PCR system 2400 (Perkin-Elmer, Saint-Quentin en
Yvelines, France). Amplification and electrophoresis of PCR
products were performed with 3 mM MgCl2 for all experi-
ments, following described procedures [13,15], at either low
or high stringency, depending on the primers used: 52C
with the erm(A), erm(C), vat(B) and vat(C) primers; 56C with
the vat(A) primers; and 58C with the vga(A), vga(B) and
vgb(A) primers.
Antibiotic susceptibility testing
Isolates were subcultured on trypticase soya agar, supplemen-
ted with whole horse blood 5% v ⁄v, and incubated for 18 h in
ambient air at 37C before testing. A bacterial suspension was
adjusted to a 0.6· McFarland standard in 2.5 mL of NaCl
0.45% w ⁄v with an ATB 1550 densitometer (bioMe´rieux). Each
0.6· McFarland suspension was diluted automatically to
2.107 CFU ⁄mL in NaCl 0.45% w ⁄v. AST-P515 cards were
filled automatically by a vacuum device, sealed and inserted
into the VITEK2 reader–incubator module (35.5C). The AST-
P515 card used for the staphylococci contained erythromycin,
clindamycin, lincomycin and pristinamycin. Quinupristin–
dalfopristin was not available in the VITEK2 cards at the time
of the study. Antimicrobial concentration ranges and break-
points used are shown in Table 1.
The agar dilution reference method for erythromycin,
clindamycin, lincomycin and pristinamycin was performed
according to the recommendations of the Comite´ de l’Antibi-
ogramme de la Socie´te´ Franc¸aise de Microbiologie (CA-SFM)
[16]. Antimicrobial concentration ranges and breakpoints used
are shown in Table 1.
Erythromycin and pristinamycin (Pyostacine) were pro-
vided by Aventis (Romainville, France). Lincomycin and
clindamycin were provided by Sigma (Saint Louis, MO,
USA).
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Analysis of susceptibility tests
Isolates were defined as susceptible, intermediately-resistant
or resistant according to CA-SFM criteria. The breakpoints
were used to calculate very major errors (VMEs), major errors
(MEs) and minor interpretation errors (mEs) between the
VITEK2 system and the reference method. VMEs occurred
when the VITEK2 results indicated susceptibility, compared
with resistance by the reference method; MEs occurred when
the VITEK2 system indicated resistance, compared with
susceptibility by the reference method; and mEs occurred
when the results by one system indicated susceptibility or
resistance, while the other system indicated intermediate
resistance.
RESULTS
Phenotypes and genotypes of isolates
Of the 57 isolates resistant to erythromycin, 27
(24S. aureus and three S. epidermidis) had theMLSrBC
phenotype. Of these, 23 S. aureus and two S. epider-
midis isolates had the erm(A) gene, one S. aureus
isolate had the erm(A)–erm(C) association, and one
S. epidermidis isolate had the erm(C) gene. The three
S. aureus isolates with an inducible MLSB resistance
phenotype had the erm(C) gene.
Of the 27 isolates (15 S. aureus and 12 S. epider-
midis) showing resistance to pristinamycin in
association with constitutive MLSB resistance
(MLSBC SgA PT
r phenotype), 20 (11 S. aureus and
nine S. epidermidis) harboured the erm(A) gene, four
(three S. aureus and one S. epidermidis) the erm(C)
gene, and three (oneS. aureus and twoS. epidermidis)
had the erm(A)–erm(C) association. Of the 15
S. aureus isolates, seven had the vga(B) gene, seven
had the vat(A)–vgb(A) association, and one had the
vgb(A) gene. Among the 12 S. epidermidis isolates,
nine had the vga(A) gene, one had the vga(B) gene
and one had the vga(A)–vga(B) association.
Of the 23 isolates susceptible to erythromycin,
the two S. aureus isolates that were resistant to
pristinamycin alone (the SgA SgB PT resistance
phenotype) had the vat(A)–vgb(A) association.
The S. aureus isolate resistant to lincosamides
and streptogramins (L SgA SgB PTr phenotype)
carried the vat(A) and vgb(A) genes. A lincos-
amide and streptogramin A (L SgAr) resistance
phenotype was observed for 17 S. aureus and
three S. epidermidis isolates. No specific resistance
gene was found among the S. aureus isolates, but
two S. epidermidis isolates had the vga(B) gene.
Comparison between the VITEK2 system and
the agar dilution method
The overall results of susceptibility testing
obtained with the VITEK2 system for 80 staphylo-
coccal isolates (320 single susceptibility tests) are
presented in Table 2. Essential agreement, based
Table 1. Concentration ranges of antimicrobial agents and
breakpoints used in the VITEK2 AST-P515 card
Antimicrobial agents
MIC (mg/L) range
determined by:
Breakpointsa
(mg/L)
VITEK2 Referenceb c C
Erythromycin 0.25–8 0.02–64 1 > 4
Lincomycin 2–16 0.02–64 2 > 8
Clindamycin 0.25–8 0.02–64 2 > 2
Pristinamycinc 0.5–8 0.02–64 1 > 2
aSusceptible MIC £ c; resistant MIC > C [9].
bAgar dilution.
cPristinamycin (Pyostacine).
Table 2. Performance of the VITEK2 system for antimi-
crobial susceptibility testing of 80 staphylococcal isolates
compared with the agar reference method
Resistance phenotype,
microorganism
(n) and antimicrobial agent
No. of
tests
No. of isolates
with VITEK2
susceptibility No. of errors
S I R VME ME mE
MLSrBC
S. aureus (24) + S. epidermidis (3)
Erythromycin 27 0 0 27 0 0 0
Lincomycin 27 0 0 27 0 0 0
Clindamycin 27 0 0 27 0 0 0
Pristinamycin 27 4 22 1 0 1 22
MLSBi L SgA
r
S. aureus (3)
Erythromycin 3 0 0 3 0 0 0
Lincomycin 3 0 3 0 0 0 3
Clindamycin 3 3 0 0 0 0 0
Pristinamycin 3 0 3 0 0 0 3
MLSBC SgA PT
r
S. aureus (15) + S.epidermidis (12)
Erythromycin 27 0 0 27 0 0 0
Lincomycin 27 0 0 27 0 0 0
Clindamycin 27 0 0 27 0 0 0
Pristinamycin 27 0 0 27 0 0 0
SgA SgB PTr
S. aureus (2)
Erythromycin 2 2 0 0 0 0 0
Lincomycin 2 2 0 0 0 0 0
Clindamycin 2 2 0 0 0 0 0
Pristinamycin 2 0 0 2 0 0 0
L SgA SgB PTr
S. aureus (1)
Erythromycin 1 1 0 0 0 0 0
Lincomycin 1 0 1 0 0 0 0
Clindamycin 1 1 0 0 0 0 0
Pristinamycin 1 0 0 1 0 0 0
L SgAr
S. aureus (17) + S. epidermidis (3)
Erythromycin 20 20 0 0 0 0 0
Lincomycin 20 16 4 0 1 0 14
Clindamycin 20 20 0 0 0 0 0
Pristinamycin 20 1 16 3 0 0 18
Total of tests 320
S, susceptible; I, intermediate; R, resistant; VME, very major error, susceptible with
the VITEK2 system and resistant with the agar dilution method; ME, major error,
resistant with the VITEK2 system and susceptible with the agar dilution method;
mE, minor error, susceptible or resistant with one system and intermediately-
resistant with the other system.
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on MIC comparison, was 96% for erythromycin,
79% for lincomycin, 100% for clindamycin and
48% for pristinamycin. Full agreement was found
in 258 (81%) of 320 tests. Erythromycin and
clindamycin results agreed for all the isolates.
Lincomycin results agreed for 62 (78%) and
pristinamycin results agreed for 37 (46%) of the
80 isolates.
Comparison of VITEK2 with agar dilution
identified 44 isolates that yielded discordant
results: 18 isolates with two (lincomycin and
pristinamycin) different results; and 26 isolates
with one (pristinamycin) different result. There
were thus 62 (19%) discrepant results in a total
of 320 tests. These included one VME with
lincomycin, one ME with pristinamycin and 60
mEs (17 with lincomycin and 43 with pristina-
mycin).
Of the isolates resistant to erythromycin, 22 (19
S. aureus and three S. epidermidis isolates) of 27
isolates with the MLSrBC phenotype were interme-
diately-resistant with the VITEK2 system, but
susceptible with the agar method (classed as an
mE). The three S. aureus isolates with the MLSrBi
phenotype were resistant to erythromycin and
susceptible to clindamycin without discrepancies.
However, these three isolates gave mE results, as
they were susceptible and intermediately-resist-
ant to lincomycin, and susceptible and interme-
diately-resistant to pristinamycin with the
VITEK2 system and the agar reference method,
respectively (Table 2). No discordant results were
observed for isolates with the MLSBC SgA PT
r
phenotype.
Among the isolates susceptible to erythromy-
cin, resistance to streptogramins was detected in
two S. aureus isolates with the SgA SgB PTr
phenotype without discordant results. The
S. aureus isolate with the L SgA SgB PTr pheno-
type was intermediately-resistant to lincomycin
and resistant to pristinamycin with both systems.
Among the 20 L SgAr isolates, there were 14 mEs
with lincomycin, since 14 isolates were found to
be susceptible with the VITEK2 system, but were
intermediately-resistant with the agar reference
method. Eighteen mEs were observed with pri-
stinamycin: 16 L SgAr S. aureus isolates, interme-
diately-resistant with the VITEK2 system, were
found to be susceptible with the agar reference
method, and two L SgAr S. epidermidis isolates,
resistant with the VITEK2 system, were interme-
diately-resistant with the reference method.
DISCUSSION
The purpose of this study was to evaluate the
reliability of the VITEK2 system for testing the
susceptibility of clinical isolates of S. aureus and
S. epidermidis to erythromycin, lincomycin, clin-
damycin and pristinamycin. The results were
compared with those obtained by the agar
dilution method, using the CA-SFM breakpoints.
When CA-SFM interpretative categories were
applied to the MICs obtained with the VITEK2
system, there were 18% mEs, 0.5% MEs and
1.3% VMEs. The mEs occurred with lincomycin
and pristinamycin, leading to false-susceptible
results for lincomycin and false-intermediate
results for pristinamycin. As reported previ-
ously [17], there was total agreement for eryth-
romycin and clindamycin.
The present susceptibility testing results were
obtained with known resistance genotypes for
MLS antibiotics. As reported previously [15], the
MLSBC phenotype was associated with the erm(A)
gene in 83% of the isolates, and these were
reported as intermediately-resistant to pristina-
mycin with the VITEK2 system, but susceptible
with the agar dilution method. No gene confer-
ring resistance to streptogramins was detected in
the 27 MLSrBC isolates. All 27 MLSBC SgA PT
r
isolates were reported as resistant to pristinamy-
cin, with no discordant results. The
MLSBC SgA PT
r S. aureus isolates harboured
either the vat(A)–vgb(A) combination [9] or the
vga(B) gene. Seven MLSB SgA PT
r S. aureus
isolates carried the vga(B) gene alone, a finding
which has not been reported previously, since the
vga(B) gene has always been associated with
vga(Av)–vat(B) [9]. PCR was not performed for
vga(Av), since the sequence of the gene was not
available at the time of this study. The vat(B) gene
was not detected in any isolate. Most of the
MLSB SgA PT
r S. epidermidis isolates harboured
the vga(A) gene, as reported previously [1,15].
Among the MLSB SgA PT
r S. epidermidis isolates,
12 of 14 isolates tested by Allignet et al. [1], and
seven of ten isolates tested by Lina et al. [15] were
reported to carry the vga(A) gene alone. The
S. aureus isolates resistant to streptogramins and
pristinamycin (two SgA SgB PTr and one
L SgA SgB PTr) were reported as resistant with
both the VITEK2 system and the agar dilution
method. These three isolates carried the vat(A)–
vgb(A) combination, as reported previously [1,9].
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Clinical isolates of S. aureus susceptible to
macrolides and streptogramin B, but resistant to
lincomycin and streptogramin A (L SgAr
strains), were described for the first time in
France in 1980 [9,18]. Most of those strains are
susceptible to clindamycin and have low-level
resistance to pristinamycin. In the present study,
16 of 20 tested L SgAr isolates appeared to be
susceptible to lincomycin with the VITEK2
system, but intermediately-resistant with the
agar dilution method (mE). Curiously, similar
low levels of pristinamycin resistance were
detected with the VITEK2 system; thus, the 17
L SgAr S. aureus isolates were susceptible to
pristinamycin with the agar dilution method
(pristinamycin median MIC of 0.5 mg ⁄L), but
intermediately-resistant with the VITEK2 system
(pristinamycin median MIC of 2 mg ⁄L). The
three L SgAr S. epidermidis isolates intermedi-
ately-resistant or resistant to pristinamycin with
the agar dilution method were resistant with the
VITEK2 system. All the L SgAr isolates were
resistant to streptogramin A with the agar
dilution method (pristinamycin IIA median
MIC of 32 mg ⁄L vs. 4 mg ⁄L for the S. aureus
25923 ATCC strain). No gene conferring resist-
ance to streptogramin A was found in the
L SgAr strains. A variant of the vga(A) gene,
vga(Av), has been described by Haroche et al.
[8]. The sequence of the variant gene was
similar to that of the vga(A) gene (83.2%
identity). The vga(Av) gene alone was detected
in 14 L SgAr S. aureus isolates, and in six
MLSBC SgA PT
r S. aureus isolates [9]. Curiously,
two of the three L SgAr S. epidermidis isolates in
the present study carried the vga(B) gene, which
has not been described in S. epidermidis previ-
ously.
In summary, the present study demonstrated
that: (1) the VITEK2 system is a reliable method
for testing the susceptibility of clinical isolates of
staphylococci to erythromycin and clindamycin;
(2) pristinamycin susceptibility tests with the
VITEK2 system are reliable for L SgAr isolates,
but unreliable for MLSrB isolates; (3) lincomycin
susceptibility tests with the VITEK2 system are
unreliable for L SgAr isolates; and (4) resistance to
pristinamycin in S. aureus and S. epidermidis is
usually associated with the vat(A), vga(A), vga(B)
and vgb(A) genes, either alone or in combina-
tion with the vga(B) and vat(A)–vgb(A) genes in
S. aureus, and with vga(A) in S. epidermidis.
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